Thursday, September 10, 2026

UN General Assembly Hosts Rare Debate on North Korea’s Human Rights Violations

The UN's first high-level meeting on North Korean human rights, with South Korean participation, spotlighted systemic violations and global concerns.

South Korea Begins Its First Advanced Regenerative Medicine Treatment Using ViGenCell Therapy

ViGenCell’s VT-EBV-N has begun South Korea’s first approved advanced regenerative medicine treatment, giving patients with high-risk EBV-positive lymphoma access to a personalized T-cell therapy while generating real-world clinical and manufacturing data.

Will Cha Eun Woo Star in Seorabeol Knife? Latest Updates on His Next Project

Astro member Cha Eun Woo's agency confirms he is considering a role in the drama Seorabeol Knife.

Tag: Alteogen

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Alteogen Signs Subcutaneous Injection Development Deal With Novartis Worth Up to $3.22 Billion

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

Alteogen Signs $365 Million License Deal With Global Pharma Company for SC Platform Technology

Alteogen has signed an exclusive licensing agreement with a global pharmaceutical company for the development of subcutaneous biopharmaceuticals.

Alteogen CEO Says Additional Licensing Deals Near Completion, Highlights Patent Strength [BIO USA]

Alteogen is nearing global licensing deals, focusing on maximizing value and expanding its platform technology in biopharma.

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Alteogen Secures U.S. Patent for Keytruda Subcutaneous Injection: What This Means for ALT-B4 and Future Treatments

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.